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ackground: Pseudomonas aeruginosa (Ps. aeruginosa) is considered as an opportunistic pathogen and 
the leading cause of morbidity and mortality in immunocompromised individuals. Globally, approximately 
10-15% of the nosocomial infections are caused by Ps. aeruginosa. The Ps. aeruginosa can acquire 
resistance against broad-spectrum antibiotics. According to recent studies increased mortality has been 
observed due to infection with extended-spectrum-beta-lactamase (ESBL) producing Ps. aeruginosa strains. 
This study was designed to determined antibiogram of ESBL producing multi-drug resistant Ps. aeruginosa in 
Khyber Pakhtunkhwa. 
Methods: The clinical confirmed Ps. aeruginosa samples were collected according to the standard protocol, at 
Khyber Teaching Hospital (KTH), Peshawar. All collected samples were sub- cultured on appropriate culture 
media. After isolation and identification, the antibiotics susceptibility testing was performed. The detection of 
ESBL was carried out by the double-disc diffusion method. Carbapenemase-producing bacteria was confirmed 
by the modified Hodge test. Descriptive analysis was performed for statistical analysis of collected data.  
Results: A total of one hundred and sixty-two (n=162) Ps. aeruginosa confirmed isolates were collected, in which 
59.3% were male and 40.7% were from female patients. The percentages of ESBL and carbapenemase 
producing Ps. aeruginosa isolates were 5.5% and 23.5%, respectively. The multidrug resistance was observed 
against 27.2% isolates. Among tested antibiotics highest percentages of resistance was observed against 
ciprofloxacin (43%) and ceftazidime (39.5%).   
Conclusion: We observed highest level of drug resistance in Ps. aeruginosa clinical isolates against tested 
antibiotics and majority of the isolates were Multi-drug resistant (MDR). 
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Introduction  
Pseudomonas aeruginosa (Ps. aeruginosa) is a gram-
negative, rod shaped, non-lactose fermenter and 
opportunistic pathogen. As an opportunistic pathogen it 
is considered as a leading cause of morbidity and 
mortality [1]. It causes both hospital and community-
acquired infections [2]. Worldwide approximately 10-
15% of the nosocomial infections are caused by Ps. 
aeruginosa [3]. Various virulence factors that contribute 
in its pathogenesis are endotoxins, exotoxins, ability to 
produce biofilm and different enzymes [4]. Usually, for 
the treatment of Ps. aeruginosa  infections broad 
spectrum antibiotics such as carbapenems, extended-
spectrum cephalosporin,  anti-pseudomonal  penicillin, 
and polymyxin B/colistin are used [5]. With the passage 
of time theses antibiotics acquired resistance due to over 
use or misuse of these antimicrobial agents [3]. Other 
factors that contribute in its increase resistance are 
production of beta-lactamase enzymes such as 
extended spectrum beta lactamases (ESBLs) and 
metallo-beta-lactamases (MBLs), target site 
modification, efflux pump and biofilm formation  [6]. The 
Ps. aeruginosa acquire resistance by intrinsic as well as 
extrinsic mechanism [7]. As a result increase in morbidity 
and mortality have been observed from the infections of  
multi drug resistant (MDR) Ps. aeruginosa  [8].  
Globally, the prevalence of ESBL and carbapenemase 
producing Ps. aeruginosa have been reported [9]. The 
infections caused by MDR Ps. aeruginosa are difficult to 
treat. It is important to periodically check the antibiotic 
susceptibility patron of important clinical pathogens that 
will improve empirical treatment of clinical infections. 
Therefore, this study was conducted to evaluate the 
antibiotic susceptibility profile and phenotypic detection 
of ESBL and carbapenemase enzyme among clinical 
isolates of Ps. aeruginosa.  
Methods 
This study was carried out in Khyber Teaching Hospital, 
Peshawar from February to September 2019.  A total of 
one hundred and sixty-two (n=162) Ps. aeruginosa 
confirmed samples were collected. The Ps. aeruginosa 
strains were isolated from blood, bone marrow, fluids, 
pus, sputum, tissue, urine, and wound etc. The collected 
strains were sub-cultured on Blood agar and MacConkey 
agar (OXIDE England) and incubated overnight. The 
isolated strains were confirmed by standard 
microbiological procedures such as colony morphology, 
Gram staining, and biochemical testing. 
The antibiotic susceptibility testing was carried out by 
Kirby-Bauer disc diffusion method as per CLSI, 2018 
recommended guidelines [10]. The antibiotic discs and 
concentrations used were as follows; ciprofloxacin (5μg), 
gentamicin (10μg), imipenem (10μg), sulzone (100µg), 
meropenem (10μg), ceftazidime (30μg), tazocin (100µg), 
amikacin (30μg) and polymyxin B/colistin (10µg). The 
bacterial suspension was prepared in a sterile normal 
saline solution and compared with 0.5 McFarland's 
turbidity standard.  The tested antibiotic discs were 
placed on Muller Hinton agar (OXIDE England) plate and 
overnight incubated at 37C. The zone size interpretation 
was carried out as per CLSI guidelines 2018 [10]. The 
Ps. aeruginosa ATCC 27853 reference strain was used 
as quality control.  The imipenem resistant strains were 
tested for carbapenemase production by modified Hodge 
test [11]. ESBL detection was carried out by double disc 
synergy method. The disc used were amoxicillin 
clavulanic acid, cefotaxime and ceftazidime [12].  
All the data were analyzed through statistical package for 
social science software version 21. The descriptive 
analysis (percentage and number) were performed for 
collected data. 
Results 
A total of one hundred and sixty-two (n=162) confirmed 
isolates of Ps. aeruginosa were collected in which 59.3% 
were from male and 40.7% were from female patients. In 
this study, age wise the patients were categorized into 
eight groups (Table no.1). Majority of the Ps. aeruginosa 
were recovered from the age grouped between 21-30 
years. 
Age 
(Years) 
Male % (n) Female % 
(n) 
Total (Male + Female) % 
(n) 
0-10 10.4 (10) 9.1 (6) 9.9 (16) 
11-20 9.4 (9) 7.6 (5) 8.6 (14) 
21-30 14.6 (14) 25.7 (17) 19.1 (31) 
31-40 11.5 (11) 9.1 (6) 10.5 (17) 
41-50 11.5 (11) 13.6 (09) 12.4 (20) 
51-60 17.7 (17) 10.6 (07) 14.8 (24) 
61-70 18.7 (18) 16.7 (11) 17.9 (29) 
≥70 6.2 (6) 7.6 (5) 6.8 (11) 
Total 59.3 (96) 40.7 (66) 100 (162) 
Table 1: Age & gender wise distribution of Ps. aeruginosa clinical 
isolates in patients attending KTH. 
The strains of Ps. aeruginosa were collected from nine 
different clinical samples (Shown in table no. 2), which 
includes; Urine 34.0% (n=55), Pus 30.2% (n=49), 
Sputum 24.1% (n=39), Wound 04.3% (n=07), Tissue 
1.2% (n=2), Blood 2.5% (n=4), Bone marrow 1.9% (n=3), 
Fluid 1.2% (n=2) and CSF 0.6% (n=1). The highest 
number of specimens were collected from urine 
samples. All the isolates (n=162) were tested for the 
antibiogram against commonly prescribed antibiotics 
used in our locality and overall MDR has been observed 
as shown in table no 3.  
Among the tested isolates 27.16% isolates were MDR 
(The isolates showed resistance to at least one antibiotic 
in three or more antimicrobial classes were classified as 
Multidrug resistant Ps. aeruginosa). Overall, 23.4% and 
5.5% of the isolates were carbapenemase and ESBL 
producers respectively. 
Discussion  
The Ps. aeruginosa is a non-fermenting multidrug 
resistant pathogen and the main cause of hospital and 
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community-acquired infections [13]. The prevalence of 
resistant strains varies in different regions. In this study, 
the increase prevalence of Ps. aeruginosa infection was 
recorded in patients with age group of 21-30 years 
(19.1%), followed by 61-70 years (17.9%). A study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
conducted at Peshawar in 2017, revealed that age group 
41-61 years have a high prevalence (36.6%) of Ps. 
aeruginosa infection, which are not in consistence with 
the current study [14]. The possible reason that caused 
difference could be origin of bacterial isolation.
Sample Male %(n) Female%(n) Total (Male + Female) %(n) ESBL%(n) Carbapenemase %(n) MDR%(n) 
Blood 3.1 (3) 1.5 (1) 2.5 (4) 00 (00) 5.2 (2) (00) 
Bone 2.1 (2) 1.5 (1) 1.9 (3) 11 (1) 5.2 (2) 4.5 (2) 
CSF 1.0 (1) 00 (00) 0.6 (1) 00 (00) 00 (00) 00 (00) 
Fluid 2.1 (2) 00 (00) 1.2 (2) 00 (00) 00 (00) 00 (00) 
Pus 32.3 (31) 27.3 (18) 30.2 (49) 44.5 (04) 15.9 (6) 20.5 (09) 
Sputum 21.9 (21) 27.3 (18) 24.1 (39) 00 (00) 34.2 (13) 31.8 (14) 
Tissue 2.1 (2) 00 (00) 1.2 (2) 00 (00) 00 (00) 00 (00) 
Urine 31.2 (30) 37.9 (25) 34 (55) 44.5 (04) 34.2 (13) 40.9 (18) 
Wound 4.2 (4) 4.5 (3) 4.3 (7) 00 (00) 5.2 (2) 2.3 (1) 
Total 59.3 (96) 40.7 (66) 100 (162) 5.5 (9) 23.5 (38) 27.2 (44) 
Note:  n: Sample number, %: percentage, MDR: Multi-Drug Resistant 
Table 2: Specimen wise distribution of Ps. aeruginosa strains isolated from patients attending KTH. 
Variants  Male   n=96 %(n) Female n=66 %(n) Total n=162 %(n) 
ESBL 5.2 (05) 6.0 (04) 5.6 (09) 
Carbapenemase 25 (24) 21.2 (14) 24.5 (38) 
MDR 32.3 (31) 19.7 (13) 27.2 (44) 
Ciprofloxacin 50 (47) 33.3 (22) 43 (69) 
Gentamicin 39.6 (38) 28.8 (19) 35.2 (57) 
Suzlon 36.4 (35) 27.3 (18) 32.7 (53) 
Imipenem 37.5 (36) 25.8 (17) 32.7 (53) 
Meropenem 37.5 (36) 27.3 (18) 33.3 (54) 
Ceftazidime 41.7 (40) 36.4 (24) 39.5 (64) 
Tazocin 37.5 (36) 31.8 (21) 35.2 (57) 
Amikacin 38.5 (37) 27.3 (18) 34 (55) 
Colistin/polymyxin 16.7 (16) 15.2 (10) 16 (26) 
Note:  ESBL: Extended Spectrum Beta lactamases, MDR: Multi-Drug Resistant, n: sample number, %: percentage. 
Table 3:  Resistance determinants of Ps. aeruginosa clinical isolates among patients attending KTH. 
No of resistant antibiotics  Male (n=96) %(n) Female (n=66) %(n) Total (male and female) n=162) %(n) 
R-0 45.8 (44) 56.1 (37) 50 (81) 
R-1  6.3 (6) 4.5 (3) 5.5 (09) 
R-2 5.2 (5) 7.6 (5) 6.2 (10) 
R-3 7.3 (7) 4.5 (3) 6.2 (10) 
R-4 9.4 (9) 3 (2) 6.8 (11) 
R-5 4.2 (4) 1.5 (1) 3.1 (05) 
R-6 4.2 (4) 9.1 (6) 6.2 (10) 
R-7 5.2 (5) 3.0 (2) 4.3 (07) 
R-8 11.5 (11) 9.1 (6) 10.5 (17) 
R-9 00 (00) 3 (2) 1.2 (2) 
Note:  R-0: No resistance, R-1: Resistant to single antibiotic, R-2: Resistant to two antibiotics, R-3: Resistant to three antibiotics, R-4: 
Resistant to four antibiotics, R-5: Resistant to five antibiotic, R-6: Resistant to six antibiotics, R-7: Resistant to seven antibiotics, R-8: 
Resistant to eight antibiotics, R-9: Resistant to nine antibiotics 
Table 4: Antibiotic resistance combination among Ps. aeruginosa isolated from patients. 
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A study conducted at Karachi, Pakistan, showed that 
infection caused by Ps. aeruginosa is more prevalent in 
females (64.71%) than in men (35.29%) [15]. 
Comparatively we observed low prevalence among 
females. In our study, the resistance against 
Ciprofloxacin, Gentamicin, Imipenem, Suzlon, 
Meropenem, Ceftazidime, Tazocin, Amikacin and 
Colistin were 43%, 35.2%, 32.7%, 32.7%, 33.3%, 39.5%, 
35.2%, 34%, and 16%, respectively. A study conducted 
in 2009 at North West region of Pakistan, showed 
resistance against Amikacin (70%), Gentamicin (25%), 
and Ciprofloxacin (49%) [16]. In correlation to this study, 
the resistance against Amikacin is less. Another study 
carried out at Burn Center Islamabad in 2015, reported 
resistance to Tazocin (Piperacillin and Tazobactam) 
80.55%, Imipenem (63.88%), Ciprofloxacin (44.44%), 
Polymyxin/colistin (36.11%), Suzlon (Cefoperazone and 
Sulbactam) 30.55%, ceftazidime (11.11%) and Amikacin 
(8.33%) [17]. We observed a low level of resistance 
against Amikacin and Ceftazidime. The reported 
resistance in another study were as follows; 
Ciprofloxacin (60%), Cefepime (57%), Levofloxacin 
(56%), Ceftazidime (53.9%), Amikacin (53%), 
Gentamicin (51%) and Tazobactum/Piperacillin 
81(37.9%) [16]. 
The reported frequency of carbapenemase and ESBL 
producer from Lahore was 3.4% and 12.5% respectively, 
and all the strains were  multidrug-resistant [18]. Our 
results of ESBL are in consistence with the previous 
report whereas a slight increase have been observed in 
case of carbapenemase.  The frequency of MDR-ESBL 
and MDR-carbapenemase were almost similar with the 
results of the previous study. Ullah et.al. at Peshawar in 
2014  reported the frequency of MDR 2.75% 
(n=102/3700) [19].   
Conclusively, we identified Ps. aeruginosa clinical 
isolates from a tertiary care hospital. Majority of the 
studied isolates were ESBL producers and MDR. This 
increase prevalence of MDR will lead to treatment failure 
of infection caused these strains. This study 
recommends development of alternative treatment 
regimen.  Furthermore, periodical surveillance and 
observation of resistance to antimicrobial agents at local 
and national level will be better for management of 
bacterial infections and for effective empirical therapy.   
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